BioNTech SE · NASDAQ:BNTX
BioNTech — Shareholder Meeting (June 2022)
40 slides from BioNTech's shareholder meeting presentation, Jun 2, 2022
Slide 1: Annual General Meeting 2022
June 1st, 2022 Annual General Meeting 2022 English Convenience Translation: German language is decisive.
Slide 2: Financial and operating development and outlook 2022
FINANCIAL DEVELOPMENT 2021 / Q1 2022 AND FINANCIAL OUTLOOK 2022 Jens Holstein, CFO OPERATING DEVELOPMENT 2021 / Q1 2022 AND OPERATING OUTLOOK 2022 Prof. Dr. Ugur Sahin, CEO & Founder
Slide 3: Operating Development 2021 & Q1 2022 and Operating Outlook 2022
OPERATING DEVELOPMENT 2021 & Q1 2022 AND OPERATING OUTLOOK 2022
Slide 4: This Slide Presentation Includes Forward-looking Statements
This Slide Presentation Includes Forward-looking Statements 4 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: our expected revenues and net profit relat
Slide 5: Safety Information
Safety Information 5 COMIRNATY® ▼(the Pfizer-BioNTech COVID-19 vaccine) has been granted conditional marketing authorization (CMA) by the European Commission to prevent coronavirus disease 2019 (COVID-19) in people from 5 years of age. The vaccine is administered as a primary course of 2 doses, 3 we
Slide 6: Safety Information: Authorized Use in the U.S.
Safety Information 6 AUTHORIZED USE IN THE U.S. COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and old
Slide 7: Harnessing the power of the immune system
Harnessing the power of the immune system to develop novel therapies against cancer, infectious diseases and other severe diseases.
Slide 8: BioNTech Today: A 21st Century Immunotherapy Powerhouse
BioNTech Today | A 21st Century Immunotherapy Powerhouse 8 Technology-agnostic Multi-Platform Strategy Diversified Product Pipeline Fully Integrated Biotechnology Company Our Approach to Global Social Responsibility Focus on high medical needs. Democratize access to novel medicines.
Slide 9: 2021: Key Highlights of Progress Towards Vision
2021: Key Highlights of Progress Towards Vision 9 STRONG FINANCIAL PERFORMANCE €19.0 Bn Total 2021 Revenues2 €39.63 Diluted EPS2 EXPANDED GLOBAL ORGANIZATION 3,000+ team members >1 bn to low- and middle- income countries1 Increased footprint with new offices in U.S., Europe and Asia COMIRNATY - GLOB
Slide 10: 2021: A Year of Historic Impact
Titelmasterformat durch Klicken bearbeiten 2021: A Year of Historic Impact 10 1Approved for emergency use/temporary supply or Conditional Marketing Authorization in more than 90 countries worldwide including the U.S. and EU, December 2021 2 Doses shipped in first year after launch; 3 As of mid Decem
Slide 11: 2021: A Year of Transformation & Progress
2021: A Year of Transformation & Progress Production capacity Expansion of R&D and production teams Nine oncology clinical trials started; clinical results from six phase 1 studies Expansion of commercial scale mRNA production and addition of US cell therapy manufacturing facility Established office
Slide 12: Diversity – Important Success Factor
Diversity – Important Success Factor 3,000 employees1 60 nationalities 1,200 new colleagues Seven sites in Germany Cambridge, USA Gaithersburg, USA Istanbul,Turkey Singapore Shanghai, China Reading, UK Vienna, Austria Twelve subsidiaries worldwide Mainz (Hauptsitz) Berlin Marburg Halle Idar-Oberstei
Slide 13: Global Social Responsibility at Our Core
Global Social Responsibility at Our Core 13 COVID-19 vaccine pledge to COVAX and the world • 2+ bn doses to low- and middle-income countries by end of 2022 Development of new drugs for diseases with high unmet medical need in low-income countries • Malaria • Tuberculosis • HIV Start to establish mRN
Slide 14: Multi-Platform Strategy
SZ NF MULTI-PLATFORM STRATEGY BIONT=CH
Slide 15: Multi-platform Strategy: Toolbox for Innovation
Multi-platform Strategy: Toolbox for Innovation 15 Collaboration Internal technology Digital & AI capabilities SELECTIVE TLR-7 ANTAGONISM SMALL MOLECULES NEXT GEN IMMUNO- MODULATORS Bispecific antibodies TARGETED CANCER THERAPIES ANTIBODIES RIBOLYSINS Precision antibacterials (Phagomed) RIBO- LOGICA
Slide 16: Diversified Product Pipeline
BBL DIVERSIFIED | PRODUCT PIPELINE
Slide 17: Waves of Innovation Propel Us Toward Our Vision
Waves of Innovation Propel Us Toward Our Vision 17 Oncology Infectious diseases New disease areas Once in a generation opportunity to transform medicine Driving transformation TODAY Near- and mid-term Long-term FIVE RANDOMIZED PHASE 2 TRIALS One marketed vaccine 10+ PRECLINICAL PROGRAMS ONE PHASE 1
Slide 18: 2022: Success Through Further Development of the COVID-19 Vaccine
• Product optimization: new formulation • Pediatric label expansion for different age groups • Evaluation and approval of booster • Label expansion to additional at-risk groups • Future pandemic preparedness • Monitoring of emerging variants • Rapid data-guided vaccine adaptation • Development of va
Slide 19: COVID-19 Vaccine: Staying Ahead of the Virus with Innovation
COVID-19 Vaccine: Staying Ahead of the Virus with Innovation 19 Goal R&D Strategy Landscape Research Understanding dynamics of SARS-CoV-2 immunity Research program to study immune profile of anti-SARS-CoV-2 after vaccination, boosters and breakthrough infections Product Research COVID-19 follow-on a
Slide 20: Infectious Diseases: Important Area of Growth
Infectious Diseases: Important Area of Growth 20 • Tackling global health problems (malaria, tuberculosis, and HIV) • Combating diseases for which there is not yet a prophylactic vaccine or therapy Addressing a high medical need Wide range of innovative technologies • Applying new technologies, incl
Slide 21: Infectious Disease Pipeline: Expect to Start Four Clinical Trials
Infectious Disease Pipeline: Expect to Start Four Clinical Trials 21 Platform Product can didate Preclinical Phase 1 Phase 2 Phase 3 Market Milestones 2022 3 mRNA vaccines partnered with Pfizer COVID-19 Vaccine1 BNT162b2 Several updates on data Influenza1 BNT161 Data update: 2022 Shingles1 - Start P
Slide 22: Oncology: New Precision Therapies with Scaling Potential
Oncology: New Precision Therapies with Scaling Potential 22 Our innovative approach Overcoming therapeutic limitatons in the treatment of solid tumors Individualized therapeutic approaches Development of precise immuno- oncology therapies Scale of platforms across tumor indications Combination of di
Slide 23: Oncology Pipeline: Significant Progress and Expansion
Oncology Pipeline: Significant Progress and Expansion 23 Drug class Plattform Product candidate Indication (targets) Pre-clinical Phase 1 Phase 2 Phase 3 Milestones mRNA FixVac (fixed combination of shared cancer antigens) BNT111 Advanced melanoma BNT112 Prostate cancer BNT113 HPV16+ head and neck c
Slide 24: Oncology Programs in Phase 2
Oncology Programs in Phase 2 24 Platform FixVac Off-the-shelf mRNA vaccine iNeST Individualized mRNA immunotherapy Bispecific Next-generation immunotherapy Program BNT111 R/R Melanoma BNT113 HPV16+ HNSCC BNT122 Autogene cevumeran1 1L Melanoma BNT122 Autogene cevumeran1 Adjuvant colorectal cancer BNT
Slide 25: Outlook 2022
K OUTLOOK 2022 BIONT=CH
Slide 26: 2022 Strategic Priorities
2022 Strategic Priorities 26 • Initiate 4 FIH vaccine trials: • 10+ additional mRNA vaccine programs • Precision antibacterials Expand in Infectious Disease • First randomized Phase 2 readout • Prepare for registrational trials • Additional data for CAR-T cell therapy against solid tumors Execute in
Slide 27: Financial Development 2021 / Q1 2022 and Financial Outlook 2022
27 FINANCIAL DEVELOPMENT 2021 / Q1 2022 AND FINANCIAL OUTLOOK 2022
Slide 28: Key Highlights of the 2021 Financial Year
€ 2.1 bn2 + € 12.4 bn Cash + Cash Deposits and Trade Receivables € 19.0 bn € 15.3 bn € 39.63 Key Highlights of the 2021 Financial Year 28 Total Revenues1 Operating Result Diluted EPS 1 BioNTech’s profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further descri
Slide 29: Key Highlights of the 2021 Financial Year (2)
Direct COVID-19 vaccine sales to customers in BioNTech’s territory Share of gross profit and sales milestones from COVID-19 vaccine sales in the Pfizer and Fosun Pharma territory (100% gross margin) Key Highlights of the 2021 Financial Year (2) 29 € 18.8 bn COVID-19 Vaccine Commercial Revenues1: € 1
Slide 30: Key Highlights of the 2021 Financial Year (3)
€ 0.4 bn Cash deposits as of December 31, 2021 Key Highlights of the 2021 Financial Year (3) 30 € 1.7 bn Cash and cash equivalents as of December 31, 2021 Cash Cash Deposits1 € 12.4 bn Trade receivables as of December 31, 2021 Trade Receivables Funds to finance our Growth2 1 Cash deposit with an ori
Slide 31: Comparison Guidance to Actuals 2021 Financial Year
Titelmasterformat durch Klicken bearbeiten Comparison Guidance to Actuals 2021 Financial Year 31 Guidance as of Nov 2021 Actual result FY 20211 Drivers1 COVID-19 vaccine revenues € 16 - 17 bn € 19 bn • ~2.6 bn COVID-19 vaccine doses delivered in 2021 vs. up to 2.5 bn doses guided • Higher proportion
Slide 32: FY 2021 Financial Results – Profit or Loss
Titelmasterformat durch Klicken bearbeiten FY 2021 Financial Results – Profit or Loss 32 (€ in millions, except per share data)1 FY 2021 FY 2020 Research & development revenues 102.7 178.8 Commercial revenues2 18,874.0 303.5 Total revenues 18,976.7 482.3 Cost of sales (2,911.5) (59.3) Research and d
Slide 33: Key Highlights of the First Quarter of 2022
Titelmasterformat durch Klicken bearbeiten € 6.4 bn € 4.8 bn € 14.24 € 6.2 bn + € 12.7 bn 1 BioNTech’s profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further described in the Annual and Quarterly Reports. Any changes in the estimated share of the collaborat
Slide 34: Q1 2022 Financial Results – Profit or Loss
Titelmasterformat durch Klicken bearbeiten Q1 2022 Financial Results – Profit or Loss (€ in millions, except per share data)1 Q1 2022 Q1 2021 Research & development revenues 12.4 20.9 Commercial revenues2 6,362.2 2,027.5 Total revenues 6,374.6 2,048.4 Cost of sales (1,294.1) (233.1) Research and dev
Slide 35: 2022 Financial Year Guidance
2022 Financial Year Guidance 35 COVID-19 Vaccine Revenues for FY 20221 Estimated BioNTech COVID-19 vaccine revenues € 13 – 17 bn Planned FY 2022 Expenses and Capex1 R&D expenses € 1,400 - 1,500 m SG&A expenses € 450 - 550 m Capital expenditure € 450 - 550 m Estimated FY 2022 Tax Assumptions BioNTech
Slide 36: Capital Allocation Framework for the 2022 Financial Year
Titelmasterformat durch Klicken bearbeiten Accelerate R&D activities in the years to come Strengthen technology platforms and digital capabilities by collaborations and potential add-on M&A Develop global footprint and invest in manufacturing capabilities for key technologies Share repurchase progra
Slide 37: Capital Transactions in FY 2021 and until June 2022
Capital Transactions in FY 2021 and during the Period until June 2022 37 Fulfillment period Number of ordinary shares issued Share of issued share capital1 Issuing price Total issue amount Use of treasury shares At-The-Market-Offering Programm May 2021 995,8902 0.4% € 164.293 € 163.6 m3 Total number
Slide 38: Share Repurchase Program
Titelmasterformat durch Klicken bearbeiten Share Repurchase Program 1 For the share repurchase, the "share of issued common stock" ratio is calculated based on the shares issued as of April 30, 2021 (248,552,200 ordinary shares). 38 Period Number of acquired ADS Percentage of share capital1 Average
Slide 39: Outlook 2022 and Beyond
Outlook 2022 and Beyond 39 Further development of COVID-19 vaccine Accelerate late- stage oncology programs Ramp up R&D investment Pursue complementary acquisitions Expand global organization Bring long-term value to patients, shareholders and society
Slide 40: Thank you.
Thank you.